Clinical characteristics and laboratory outcomes of multiple myeloma patient infected with covid-19 in Seyed Al-Shohada Hospital in 2020-2021

Zahra Rezaiyan , Fateme Abedini, Saeede Arabzade , Maryam farzan, Amirrza manteghi nezhad, Mehran Sharifi ©

Clinical characteristics and laboratory outcomes of multiple myeloma patient infected with covid-19 in Seyed Al-Shohada Hospital in 2020-2021

کد: G-32890

نویسندگان: Zahra Rezaiyan , Fateme Abedini, Saeede Arabzade , Maryam farzan, Amirrza manteghi nezhad, Mehran Sharifi ©

زمان بندی: زمان بندی نشده!

برچسب: هماتولوژی

دانلود: دانلود پوستر

خلاصه مقاله:

Background and Aim

Multiple myeloma (MM) patients are immunocompromised, and infection is a big issue for them; therefore, the impact of covid-19 in these patients should be determined.

Methods

In a retrospective cohort study from March 2020 to October 2021, we analyzed 48 MM patients with positive SARS-CoV-2 test by polymerase chain reaction (PCR) or lung involvement confirmed by chest CT-scan hospitalized in Seyed-al-Shohada hospital, Isfahan, Iran. Patients’ symptoms, laboratory findings, treatments initiated, and living status at the end of hospitalization were collected. The association between the symptoms and living status was assessed using Fisher exact test, and the risk was reported by risk ratio (RR) and its 95% confidence interval (CI). Moreover, the differences in laboratory parameters after receiving treatment for COVID-19 between alive and deceased patients were analyzed via ANOVA/ANCOVA; the standardized mean difference (SMD) was reported to show the measure of the relationship between parameters in two groups. P less than 0.05 was considered statistical significant.

Results

Results: Of 48 MM patients with a median age of 67, 13 died during treatment. Hypertension (13%) was the most common morbidity. In laboratory findings, high amounts of CRP (SMD=0.71; 95%CI: 0.01 , 1.40; p=0.05), D-dimer (SMD=1.85; 95%CI: 0.91 , 2.77; p less than 0.001), LDH (SMD=1.35; 95%CI: 0.52 , 2.16; p=0.001), and low platelet levels (SMD=-0.97; 95%CI: -1.61 , -0.31; p=0.004) were shown in deceased patients. Furthermore, dyspnea increased death risk by about 2.5 times (RR=2.57; 95%CI: 1.04 , 6.34), but this finding was not statistically significant (p=0.08).

Conclusion

This study provided initial data to develop recommendations for MM patients with COVID-19 infection.

Keywords

COVID-19: Multiple Myeloma: Mortality

دیدگاه ها (0)

تاکنون دیدگاهی منتشر نشده است. شما اولین نفر باشید!

ارسال یک دیدگاه

ارسال دیدگاه توسط مدیریت بسته شده است.